The puzzling role of CXCR4 in human immunodeficiency virus infection

Theranostics

Volumn 3, Issue 1, 2013, Pages 18-25

  Vicenzi, Elisa ^a   Liò, Pietro ^b   Poli, Guido ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

AMD3100; CCR5; CD4; Chemokine receptor; CXCR4; HIV; Integrin

Indexed keywords

CD209 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; MARAVIROC; PLERIXAFOR; VIRUS DNA;

CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VIRUS ENTRY; VIRUS PATHOGENESIS; VIRUS STRAIN; VIRUS TRANSMISSION;

AMD3100.; CCR5; CD4; CHEMOKINE RECEPTOR; CXCR4; HIV; INTEGRIN;

CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE SYSTEM; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 84883184655     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5392     Document Type: Review

References (65)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220: 868-71.
2. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984; 224: 500-3.
3. De Cock KM, Jaffe HW and Curran JW. Reflections on 30 years of AIDS. Emerg Infect Dis. 2011; 17: 1044-8. doi:10.3201/eid/1706.100184.
4. Cicala C, Arthos J and Fauci AS. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med. 2011; 9 Suppl 1: S2. doi:10.1186/1479-5876-9-S1-S2.
5. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008; 9: 301-9. doi:10.1038/ni1566.
6. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000; 100: 587-97. doi:S0092-8674(00)80694-7 [pii].
7. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell. 2000; 100: 575-85. doi:S0092-8674(00)80693-5 [pii].
8. Soilleux EJ, Morris LS, Leslie G, Chehimi J, Luo Q, Levroney E, et al. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol. 2002; 71: 445-57.
9. Cassol E, Cassetta L, Rizzi C, Gabuzda D, Alfano M and Poli G. Dendritic Cell-Specific ICAM-3 Grabbing Nonintegrin mediates HIV-1 Infection of and Transmission by M2a-Polarized Macrophages In Vitro. Aids. 2012; in press.
10. Turville S, Wilkinson J, Cameron P, Dable J and Cunningham AL. The role of dendritic cell C-type lectin receptors in HIV pathogenesis. Journal of leukocyte biology. 2003; 74: 710-8. doi:10.1189/jlb.0503208.
11. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF and Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312: 763-7.
12. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, et al. Towards an HIV cure: a global scientific strategy. Nature reviews Immunology. 2012; 12: 607-14. doi:10.1038/nri3262.
13. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003; 348: 2186-95.
14. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov. 2003; 2: 581-7. doi:10.1038/nrd1134.
15. Bowen DL, Lane HC and Fauci AS. Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103: 704-9.
16. Lores P, Boucher V, Mackay C, Pla M, Von Boehmer H, Jami J, et al. Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1992; 8: 2063-71.
17. Feng Y, Broder CC, Kennedy PE and Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science. 1996; 272: 872-7.
18. Aiuti A, Webb IJ, Bleul C, Springer T and Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997; 185: 111-20.
19. Gruters RA, Terpstra FG, De Goede RE, Mulder JW, De Wolf F, Schellekens PT, et al. Immunological and virological markers in individuals progressing from seroconversion to AIDS. Aids. 1991; 5: 837-44.
20. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F and Tersmette M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol. 1991; 65: 356-63.
21. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. 1997; 71: 7478-87.
22. Koot M, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. Aids. 1992; 6: 49-54.
23. Moore JP. Coreceptors: implications for HIV pathogenesis and therapy. Science. 1997; 276: 51-2.
24. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC and Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells [see comments]. Science. 1995; 270: 1811-5.
25. Walker CM, Moody DJ, Stites DP and Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986; 234: 1563-6.
26. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996; 85: 1135-48.
27. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997; 385: 645-9.
28. Aasa-Chapman MM, Seymour CR, Williams I and McKnight A. Novel envelope determinants for CCR3 use by human immunodeficiency virus. J Virol. 2006; 80: 10884-9. doi:80/21/10884 [pii]10.1128/JVI.01030-06.
29. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1 [letter]. Nature. 1998; 391: 240.
30. Azim T, Saidel TJ and Brown T. Essential elements of strategic information systems to guide focused HIV responses in south and south-east Asia. Aids. 2010; 24 Suppl 3: S54-61. doi:10.1097/01.aids.0000390090.68306.8a.
31. Margolis L and Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat Rev Microbiol. 2006; 4: 312-7.
32. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS [see comments]. Ann Intern Med. 1993; 118: 681-8.
33. Low AJ, Swenson LC and Harrigan PR. HIV coreceptor phenotyping in the clinical setting. AIDS Rev. 2008; 10: 143-51.
34. Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol. 2007; 45: 279-84. doi:10.1128/JCM.01118-06.
35. Penton-Rol G, Cota M, Polentarutti N, Luini W, Bernasconi S, Borsatti A, et al. Up-regulation of CCR2 chemokine receptor expression and increased susceptibility to the multitropic HIV strain 89.6 in monocytes exposed to glucocorticoid hormones [In Process Citation]. J Immunol. 1999; 163: 3524-9.
36. Becker Y. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers--a review and hypothesis. Virus Genes. 2004; 28: 5-18. doi:10.1023/B:VIRU.0000012260.32578.72.
37. Clerici M and Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection [see comments]. Immunol Today. 1993; 14: 107-11.
38. Del Prete G, Maggi E, Pizzolo G and Romagnani S. Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today. 1995; 16: 76-80.
39. Jourdan P, Abbal C, Noraz N, Hori T, Uchiyama T, Vendrell JP, et al. IL-4 induces functional cell-surface expression of CXCR4 on human T cells. J Immunol. 1998; 160: 4153-7.
40. Valentin A, Lu W, Rosati M, Schneider R, Albert J, Karlsson A, et al. Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci U S A. 1998; 95: 8886-91.
41. Galli G, Annunziato F, Mavilia C, Romagnani P, Cosmi L, Manetti R, et al. Enhanced HIV expression during Th2-oriented responses explained by the opposite regulatory effect of IL-4 and IFN-gamma of fusin/CXCR4. Eur J Immunol. 1998; 28: 3280-90.
42. Vicenzi E, Ghezzi S, Brambilla A, Sheppard HW, Lazzarin A, Poli G, et al. CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains, and disease progression. J Infect Dis. 2000; 182: 1579-80.
43. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998; 282: 1907-11.
44. Li C, Lu SC, Hsieh PS, Huang YH, Huang HI, Ying TH, et al. Distribution of human chemokine (C-X3-C) receptor 1 (CX3CR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression. Int J Immunogenet. 2005; 32: 99-106. doi:10.1111/j.1744-313X.2005.00498.x.
45. Mariani R, Wong S, Mulder LC, Wilkinson DA, Reinhart AL, LaRosa G, et al. CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol. 1999; 73: 2450-9.
46. Gosling J, Monteclaro FS, Atchison RE, Arai H, Tsou CL, Goldsmith MA, et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci U S A. 1997; 94: 5061-6.
47. Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, et al. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature. 1997; 389: 981-5.
48. Del Corno M, Liu QH, Schols D, de Clercq E, Gessani S, Freedman BD, et al. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood. 2001; 98: 2909-16.
49. Cloyd MW, Lynn WS, Ramsey K and Baron S. Inhibition of human immunodeficiency virus (HIV-1) infection by diphenylhydantoin (dilantin) implicates role of cellular calcium in virus life cycle. Virology. 1989; 173: 581-90.
50. Kinter AL, Poli G, Maury W, Folks TM and Fauci AS. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J Virol. 1990; 64: 4306-12.
51. Vicenzi E, Bordignon PP, Biswas P, Brambilla A, Bovolenta C, Cota M, et al. Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation. J Virol. 1999; 73: 7515-23.
52. Vicenzi E, Panina-Bodignon P, Vallanti G, Di Lucia P and Poli G. Restricted replication of primary HIV-1 isolates using both CCR5 and CXCR4 in Th2 but not in Th1 CD4(+) T cells. J Leukoc Biol. 2002; 72: 913-20.
53. Mariani SA, Brigida I, Kajaste-Rudnitski A, Ghezzi S, Rocchi A, Plebani A, et al. HIV-1 envelope-dependent restriction of CXCR4-using viruses in child but not adult untransformed CD4+ T-lymphocyte lines. Blood. 2012; 119: 2013-23. doi:10.1182/blood-2010-12-325308.
54. Bacchetta R, de Waal Malefijt R, Yssel H, Abrams J, de Vries JE, Spits H, et al. Host-reactive CD4+ and CD8+ T cell clones isolated from a human chimera produce IL-5, IL-2, IFN-gamma and granulocyte/macrophage-colony-stimulating factor but not IL-4. J Immunol. 1990; 144: 902-8.
55. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, et al. The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Res Hum Retroviruses. 2012. doi:10.1089/aid.2012.0103.
56. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012. doi:10.1038/nature11519.
57. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol. 2012; 188: 5166-76. doi:10.4049/jimmunol.1102756.
58. Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K, McNally JP, et al. The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog. 2011; 7: e1001301. doi:10.1371/journal.ppat.1001301.
59. Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog. 2012; 8: e1002686. doi:10.1371/journal.ppat.1002686.
60. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol. 2000; 57: 833-9.
61. Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood. 2006; 107: 3772-8. doi:10.1182/blood-2005-09-3592.
62. Clements JE, Zink MC, Narayan O and Gabuzda DH. Lentivirus infection of macrophages. Immunol Ser. 1994; 60: 589-600.
63. Grivel JC, Shattock RJ and Margolis LB. Selective transmission of R5 HIV-1 variants: where is the gatekeeper?. J Transl Med. 2011; 9 Suppl 1: S6. doi:10.1186/1479-5876-9-S1-S6.
64. Loftin LM, Kienzle M, Yi Y and Collman RG. R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies. J Transl Med. 2011; 9 Suppl 1: S3. doi:10.1186/1479-5876-9-S1-S3.
65. Verhofstede C, Nijhuis M and Vandekerckhove L. Correlation of coreceptor usage and disease progression. Curr Opin HIV AIDS. 2012; 7: 432-9. doi:10.1097/COH.0b013e328356f6f2